SCHEMBL6183029

SCHEMBL6183029

CCOCCN1Cc2cc(Oc3ccc(O)cc3)ccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 2/20 0.41
ITGAV P06756 1/20 0.41
ALDH1A1 P00352 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
LTA4H P09960 3/20 0.38
ITGA2B P08514 1/20 0.38
AOC3 Q16853 3/20 0.38
BRD4 O60885 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
ADAM17 P78536 2/20 0.37
CNR2 P34972 1/20 0.37
LIPG Q9Y5X9 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
F10 P00742 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28608040 0.78 PRMT5 (0.39) ALDH1A1BRD4LIPGPRMT5WDR77
SCHEMBL6181740 0.77 MMP14 (0.57)
SCHEMBL8348574 0.75 AOC3 (0.34) ITGB3ITGAVALDH1A1NPSR1ITGA2B
SCHEMBL8091141 0.73 CNR2 (0.62) ITGB3ALDH1A1LTA4HITGA2BCNR2
SCHEMBL6440847 0.72 ADAM17 (0.51) ALDH1A1NPSR1AOC3ADAM17PRMT5
SCHEMBL31666958 0.71 CYP26A1 (0.51) ITGB3ITGA2BADAM17PRMT5WDR77
SCHEMBL2499130 0.71 GRM5 (0.46) ALDH1A1ADAM17CNR2LIPGPRMT5
SCHEMBL31409528 0.70 ADAM17 (0.48) ALDH1A1NPSR1ADAM17PRMT5WDR77
SCHEMBL25365239 0.69 ITGB3 (0.56) ITGB3ITGAVITGA2BKMT2A
SCHEMBL30530761 0.69 ITGB3 (0.56) ITGB3ITGAVITGA2BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919332-B2 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. (US) 2005-07-19 US disclosed
EP-1507535-A1 PYRIMIDINE-2,4,6-TRIONE METALLO-PROTEINASE INHIBITORS Pfizer Products Inc. (US) 2005-02-23 EP disclosed
US-20030232849-A1 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. 2003-12-18 US disclosed
WO-2003090751-A1 PYRIMIDINE-2, 4, 6-TRIONE METALLO-PROTEINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232849-A1 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP8, MMP9, MMP1 ITGB3 1804/4885ITGAV 3118/4885ALDH1A1 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.